PURPOSE: To use optical coherence tomography angiography (OCTA) to characterize the effects of anti-VEGF injections on treatment-naive choroidal neovascularization (CNV). METHODS: From August 2014 to May 2015, treatment-naive eyes with CNV were scanned using a prototype OCTA system on a commercially available SD-OCT device (Optovue Inc, Fremont, CA). Optical coherence tomography angiography scans were obtained before anti-VEGF injection and at follow-up visits. The CNV area and greatest linear dimension (GLD) were measured along with the maximum retinal pigment epithelial detachment (RPED) height. Changes in subretinal and/or intraretinal fluid were also assessed. RESULTS: Six eyes of six patients with treatment-naive CNV were included. Diagnoses included neovascular age-related macular degeneration, idiopathic polypoidal choroidal vasculopathy, CNV secondary to central serous chorioretinopathy and multifocal choroiditis, and macular telangiectasia Type 2 with subretinal neovascularization. After treatment, all patients with fluid on OCT initially showed a decrease in the amount of fluid. Five of six patients demonstrated decreases in CNV GLD and area with an average reduction of 23.6% and 29.8% respectively. CONCLUSION: Both CNV greatest linear dimension and area measured using OCTA decreased after anti-VEGF treatment in most patients. Optical coherence tomography angiography may be a useful tool for monitoring and quantifying the response of CNV to treatment.
PURPOSE: To use optical coherence tomography angiography (OCTA) to characterize the effects of anti-VEGF injections on treatment-naive choroidal neovascularization (CNV). METHODS: From August 2014 to May 2015, treatment-naive eyes with CNV were scanned using a prototype OCTA system on a commercially available SD-OCT device (Optovue Inc, Fremont, CA). Optical coherence tomography angiography scans were obtained before anti-VEGF injection and at follow-up visits. The CNV area and greatest linear dimension (GLD) were measured along with the maximum retinal pigment epithelial detachment (RPED) height. Changes in subretinal and/or intraretinal fluid were also assessed. RESULTS: Six eyes of six patients with treatment-naive CNV were included. Diagnoses included neovascular age-related macular degeneration, idiopathic polypoidal choroidal vasculopathy, CNV secondary to central serous chorioretinopathy and multifocal choroiditis, and macular telangiectasia Type 2 with subretinal neovascularization. After treatment, all patients with fluid on OCT initially showed a decrease in the amount of fluid. Five of six patients demonstrated decreases in CNV GLD and area with an average reduction of 23.6% and 29.8% respectively. CONCLUSION: Both CNV greatest linear dimension and area measured using OCTA decreased after anti-VEGF treatment in most patients. Optical coherence tomography angiography may be a useful tool for monitoring and quantifying the response of CNV to treatment.
Authors: Simon S Gao; Li Liu; Steven T Bailey; Christina J Flaxel; David Huang; Dengwang Li; Yali Jia Journal: J Biomed Opt Date: 2016-07-01 Impact factor: 3.170
Authors: Carl B Rebhun; Eric M Moult; Stefan B Ploner; Carlos Moreira Neto; A Yasin Alibhai; Julia Schottenhamml; Byungkun Lee; WooJhon Choi; Fareed A Rifai; Mary W Tam; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Philip J Rosenfeld; Jay S Duker; James G Fujimoto; Nadia K Waheed Journal: Ophthalmol Retina Date: 2017-10-31
Authors: Qinqin Zhang; Anqi Zhang; Cecilia S Lee; Aaron Y Lee; Kasra A Rezaei; Luiz Roisman; Andrew Miller; Fang Zheng; Giovani Gregori; Mary K Durbin; Lin An; Paul F Stetson; Philip J Rosenfeld; Ruikang K Wang Journal: Ophthalmol Retina Date: 2017 Mar-Apr
Authors: Amir H Kashani; Chieh-Li Chen; Jin K Gahm; Fang Zheng; Grace M Richter; Philip J Rosenfeld; Yonggang Shi; Ruikang K Wang Journal: Prog Retin Eye Res Date: 2017-07-29 Impact factor: 21.198
Authors: Scott M McClintic; Simon Gao; Jie Wang; Ahmed Hagag; Andreas K Lauer; Christina J Flaxel; Kavita Bhavsar; Thomas S Hwang; David Huang; Yali Jia; Steven T Bailey Journal: Ophthalmol Retina Date: 2018-03-02